Animal Health Active Pharmaceutical Ingredients Market Predicted to Reach US$ 9,162.2 Million by the end of 2025
The global animal health active pharmaceutical ingredient (API) market is expected to register an impressive expansion at 7.3% CAGR during the forecast period 2017-2025. According to recent study by Persistence Market Research (PMR), it is estimated that, the revenues from animal health API market are expected to reach worth US$ 9,162.2 Mn by 2025-end.
Limited Government Intervention Provides Smooth Flow to the Market Growth in APAC
Asia-Pacific (APAC) will be the most lucrative region in the global animal health active pharmaceutical market, and is expected to exhibit higher CAGR by 2025-end. APAC region has been identified for housing some of the largest suppliers of affordable API. To save on the production costs, the concerned governments have been taking initiatives to compel small scale API manufacturers towards shifting their production units to APAC countries such as India and China. Limited intervention of government facilitates smoother flow of market growth in these countries.
However, according to western health regulatory agencies, API imported by APAC manufactures doesn’t meet the required specification criteria set by ICH (International Conference on Harmonization). There are concerns related to the quality, safety and efficacy of such APIs.
Browse Full Research Report:
Western regulatory agencies are taking stringent actions on the APIs produced in these region. The companies engaged in production are facing challenges while bridging the gap between cost and the quality of APIs. Strict validations and guidelines set by regulatory agencies are expected to hamper the growth of API market in APAC region.
Europe to Remain the Second Largest Market for Animal Health APIs
Europe is expected to remain the second largest market for animal health active pharmaceutical ingredients. Most of the leading healthcare companies operating through Europe continuously require bulk amount of animal grade APIs. In addition, consumption of animal grade API has increased substantially over the past few years. Spain is one of the largest consumer of animal-grade antimicrobial APIs in Europe.
APIs can facilitate productivity enhancement, which is of significant value to the animal healthcare industry. Such factors are expected to augment the growth of animal health API market in EU. Stringent approval process implemented by the European Medicinal Agency (EMA) only permits registered APIs for their use in production of pharmaceuticals. This is likely to result shortage of intermediates and materials. The stringent guidelines as well as fragmented market are likely to curb the market growth of animal grade API in Europe.
Request and Download Sample Report@
https://www.persistencemarketresearch.com/samples/16972
Antiparasitics to Remain in Large Demand in the Market
-
Anti-parasitics expected to be the largely adopted active pharmaceutical ingredient in the market
-
Frequent bacterial infection to pets demands Anti-infective, which in turn projected to account for the largest revenue by 2025-end
-
Revenues from the sale of anesthetics and NSIDs will remain same as compared to the collective revenues of anti-parasitics and anti-infectives
Key market players profiled in PMR’s report include Glenmark Pharmaceutical Limited., Zoetis, Inc., Eli Lilly & Co., Sanofi Winthrop Industrie (CEPiA), Indukern, S.A., Ofichem BV, P&R S.p.A (Olon S.p.A), Lonza Group AG, Huvepharma AD, Ourofino Saude Animal, Blanver Farmoquimica E Farmaceutica S.A., Zhejiang Hisun Pharmaceutical Co., Ltd, Changzhou Yabang-Qh Pharmachem Co., Ltd., Shanghai Pharmtech Co., Ltd., Ningxia Tairui Pharmaceutical Co., Ltd., Shaanxi Hanjiang Pharmaceutical Group Co., Ltd., Sequent Scientific Ltd., NGL Fine-Chem Ltd., Omkar Speciality Chemicals Ltd., and Excel Industries Ltd.
Buy Full Eye Animal Health Active Pharmaceutical Ingredients Market Report
Comments
Post a Comment